Program Information
Diode Array Transmission Detector Systems Evaluation
D Hoffman1*, B Dyer1 , C Kumaran Nair1 , Y Katuri2 , Y Rong1 , S Benedict1 (1) University of California Davis Comprehensive Cancer Center, Sacramento, CA, (2) Scandidos, Madison, WI
Presentations
SU-F-T-326 (Sunday, July 31, 2016) 3:00 PM - 6:00 PM Room: Exhibit Hall
Purpose: A new transmission detector, Delta4 Discover, developed by Scandidos (Uppsala, Sweden) was evaluated for external photon beam verification and quality assurance. The device is an array of 4040 diodes designed to be mounted on the linac accessory tray to measure photon field shape, position and fluence during patient treatment. Interfractional measurements are compared to a baseline measurement made during delivery quality assurance. The aim of this work is to evaluate the stability of the device and its effect on the shape and magnitude of the treatment beam.
Methods: Beam profiles, percent depth dose, and beam attenuation was measured for 6, 10, and 15 MV photon beams with and without the device in place for 1x1 and 30x30 cm2 fields. Changes in profile and percent depth dose was quantified to evaluate the need to recommission the treatment beam, or account for the device with a tray factor. The stability of the radiation measurements was evaluated by measuring the deviation of each diode measurement during repeated prostate VMAT treatment delivery.
Results: Photon beam profiles changed by < 1.25% in the non-penumbra regions of the 30x30 cm2 beam. Percent depth dose curves show a 5-7% increased dose at depths < 2.5cm, but agreed within 1% at depths > 2.5cm. This indicates increased skin dose, similar to the use of a physical beam wedge. The device attenuated 6, 10, and 15 MV photon beams by 1.71±0.02%, 1.36±0.03%, and 1.17±0.03%, respectively. The diode array reproduced dosimetric measurements within 0.5% standard deviation for repeated prostate VMAT measurement.
Conclusion: The device demonstrated stabile radiation measurements, while not changing the treatment beam shape in a clinically significantly manner. Use of this device can be accounted for with a tray factor, as opposed to recommissioning the treatment beam.
Contact Email: